{"id":87814,"date":"2024-07-19T18:48:16","date_gmt":"2024-07-19T11:48:16","guid":{"rendered":"https:\/\/ps-metalsheet.com\/site\/?p=87814"},"modified":"2026-04-28T20:29:57","modified_gmt":"2026-04-28T13:29:57","slug":"in-vitro-diagnostics-market-report-2025-2030-by","status":"publish","type":"post","link":"https:\/\/ps-metalsheet.com\/site\/2024\/07\/19\/in-vitro-diagnostics-market-report-2025-2030-by\/","title":{"rendered":"In Vitro Diagnostics Market Report 2025-2030, By Product & Service, Technology, and Geo"},"content":{"rendered":"

\"IVD<\/p>\n

The regulatory pathway for an IVD depends on its risk level, with options such as 510(k) submissions, premarket approvals, and de novo classifications. In addition to premarket submissions, the FDA conducts post-market surveillance of IVDs to monitor their safety and effectiveness after they have been placed on the market. If the FDA identifies any safety or efficacy concerns, it may take regulatory action, such as requiring manufacturers to recall their products or issue warnings. This category includes tests that pose a moderate risk, such as pregnancy tests or tests used to diagnose certain diseases. For these tests, manufacturers must submit a 510(k) notification to the FDA, demonstrating that the device is substantially equivalent to a previously approved or cleared one.<\/p>\n<\/p>\n